NEW YORK--(BUSINESS WIRE)--Angioblast Systems Inc. today announced successful initial safety results following commencement of the world’s first clinical trial to use allogeneic adult stem cells obtained from an unrelated, universal donor to treat patients with congestive heart failure.
